Evidence map›Paper›PMID 24035914›Full record

ReviewNeuropharmacology2014

15 years of genetic approaches in vivo for addiction research: Opioid receptor and peptide gene knockout in mouse models of drug abuse.

Pauline Charbogne, Brigitte L Kieffer, Katia Befort

Abstract readHistorical ArticleReview
In one paragraph

Review in Neuropharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed, 2 pooled it
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

91 citing papers in PubMed, 2 syntheses or guidelines pooled it, 139 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Total-body [European journal of nuclear medicine and molecular imaging · 2026
    Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. The influence of drug class on reward in substance use disorders.Pharmacology, biochemistry, and behavior · 2024
    Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review

31 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Pauline CharbogneIGBMC Institut de Génétique et de Biologie Moléculaire et Cellulaire, CNRS UMR 7104 - Inserm U964, Illkirch F-67404, France; CNRS, UMR7104, Illkirch F-67404, France; UdS Université de Strasbourg, CNRS UMR 7104 - Inserm U964, Illkirch F-67404, France; Inserm U964, Illkirch F-67404, France.
Brigitte L Kieffer
Katia Befort
Inserm · FRInstitut de génétique et de biologie moléculaire et cellulaire · FRUniversité de Strasbourg · FR

Funding

The Role of Striosome Neurons in Mediating Opiod RewardP50DA005010 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI FANSELOW, MICHAEL S · 1987 to 2021
$30.7M
Nr4a1 and GPR88 as novel gene targets for alcoholism: mouse genetic approachesU01AA016658 · NIAAA · UNIVERSITE DE STRASBOURG · PI LAURA ADELA HARSAN · 2006 to 2026
$3.8M
Opioid system /EtOH abuse: molecular genetic manipulat.U01AA013481 · NIAAA · LAB DE GENETIQUE MOLECULAIRE DES EUCARYO · PI KIEFFER, BRIGITTE L · 2002 to 2004
$324k
NIAAA NIH HHS AA16658NIAAA NIH HHS U01 AA013481NIAAA NIH HHS U01 AA016658NIDA NIH HHS DA05010NIDA NIH HHS P50 DA005010
6 · The paper itself

Abstract

The endogenous opioid system is expressed throughout the brain reinforcement circuitry, and plays a major role in reward processing, mood control and the development of addiction. This neuromodulator system is composed of three receptors, mu, delta and kappa, interacting with a family of opioid peptides derived from POMC (β-endorphin), preproenkephalin (pEnk) and preprodynorphin (pDyn) precursors. Knockout mice targeting each gene of the opioid system have been created almost two decades ago. Extending classical pharmacology, these mutant mice represent unique tools to tease apart the specific role of each opioid receptor and peptide in vivo, and a powerful approach to understand how the opioid system modulates behavioral effects of drugs of abuse. The present review summarizes these studies, with a focus on major drugs of abuse including morphine/heroin, cannabinoids, psychostimulants, nicotine or alcohol. Genetic data, altogether, set the mu receptor as the primary target for morphine and heroin. In addition, this receptor is essential to mediate rewarding properties of non-opioid drugs of abuse, with a demonstrated implication of β-endorphin for cocaine and nicotine. Delta receptor activity reduces levels of anxiety and depressive-like behaviors, and facilitates morphine-context association. pEnk is involved in these processes and delta/pEnk signaling likely regulates alcohol intake. The kappa receptor mainly interacts with pDyn peptides to limit drug reward, and mediate dysphoric effects of cannabinoids and nicotine. Kappa/dynorphin activity also increases sensitivity to cocaine reward under stressful conditions. The opioid system remains a prime candidate to develop successful therapies in addicted individuals, and understanding opioid-mediated processes at systems level, through emerging genetic and imaging technologies, represents the next challenging goal and a promising avenue in addiction research. This article is part of a Special Issue entitled 'NIDA 40th Anniversary Issue'.

Indexed as

AnimalsBiomedical ResearchDisease Models, AnimalHistory, 20th CenturyHistory, 21st CenturyHumansMiceMice, KnockoutOpioid PeptidesReceptors, OpioidSubstance-Related DisordersOpioid PeptidesReceptors, OpioidAddictionDrugs of abuseKnockout miceOpioid peptidesOpioid receptorsReward

Identifiers

PMID24035914
PMCPMC3858501
OpenAlexW2006614558

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.